Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLYM116 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CLYM116 | EXPERIMENTAL | Subcutaneous (SC) injection of CLYM116 |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous (SC) injection of placebo |
| Name | Type | Description |
|---|---|---|
| CLYM116 | DRUG | CLYM116 to be administered by SC injection |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection |
Inclusion Criteria: * Healthy adult males and females aged 18-60 years, inclusive * Body mass index (BMI) between 18 and 32 kg/m² and weight between 45 and 110 kg * Clinically normal medical history, physical exam, ECG, and laboratory results (or abnormalities deemed not clinically significant) * W...
CLYM116 is an investigational small molecule being studied for use in healthy volunteers. It is currently in a Phase 1 clinical trial to evaluate its safety, tolerability, and pharmacokinetics in normal healthy participants. The drug is not yet approved and remains in clinical development.
CLYM116 targets APRIL, a protein involved in immune system regulation. By modulating APRIL activity, the drug may have potential therapeutic applications, though its specific intended indication has not been disclosed. The ongoing Phase 1 study focuses on healthy volunteers to assess the drug's basic properties.
CLYM116 is being developed by Climb Bio, Inc., a biopharmaceutical company traded under the ticker symbol CLYM. The company is conducting a Phase 1 clinical trial of the drug in healthy volunteers in Australia.
CLYM116 is in Phase 1 clinical development. The drug is currently being studied in a randomized, double-blind, placebo-controlled trial involving 48 healthy volunteers. This early-stage study is designed to evaluate the drug's safety and tolerability in humans.
CLYM116 is being evaluated in a Phase 1 study with the identifier NCT07248865, titled 'A Phase 1 Study of CLYM116 in Normal Healthy Volunteers.' The trial is actively recruiting participants in Australia and has an enrollment target of 48 healthy adults aged 18 years and older.